Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2477207 | 1.00 | TLR8 (0.60) | TLR8PPARGPPARAMCHR1MEN1 | |
| SCHEMBL1237415 | 1.00 | TLR8 (0.60) | TLR8PPARGPPARAMCHR1MEN1 | |
| SCHEMBL6473617 | 1.00 | TLR8 (0.60) | TLR8PPARGPPARAMCHR1MEN1 | |
| SCHEMBL30844101 | 1.00 | TLR8 (0.60) | TLR8PPARGPPARAMCHR1MEN1 | |
| SCHEMBL346563 | 0.96 | TLR8 (0.64) | TLR8PPARGPPARAMCHR1MEN1 | |
| SCHEMBL31290761 | 0.94 | TLR8 (0.63) | TLR8PPARGPPARAMCHR1MEN1 | |
| SCHEMBL347826 | 0.92 | TLR8 (0.58) | TLR8PPARGPPARAMCHR1MAPT | |
| SCHEMBL20678487 | 0.90 | TLR8 (0.51) | TLR8MCHR1MEN1NR1I2LMNA | |
| SCHEMBL27768841 | 0.88 | TLR8 (0.62) | TLR8PPARGPPARAMCHR1MAPT | |
| SCHEMBL29080839 | 0.85 | KCNA3 (0.51) | TLR8MCHR1MEN1NR1I2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560587-B2 | Bis[urea-urethane] compounds | XEROX CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7504502-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | XEROX CORPORATION (US) | 2008-07-17 | — | — | US | disclosed |
| US-7371858-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7317122-B2 | Curable trans-1,2-cyclohexane bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2008-01-08 | — | — | US | disclosed |
| US-7314949-B2 | 1,2-bis(6-(ethylhexyloxycarbonylamino)hexylaminocarbonylamino)cyclohexane; gelling agents for hot melt and phase change inks | XEROX CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7220300-B2 | Phase change inks containing bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7157601-B2 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
| US-7153349-B2 | Phase change inks containing curable trans-1,2-cyclohexane bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-7144450-B2 | Phase change inks containing trans-1,2-cyclohexane bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2006-12-05 | — | — | US | disclosed |
| US-6860928-B2 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-6835833-B2 | Alkylated tetrakis(triaminotriazine) compounds and phase change inks containing same | XEROX CORPORATION | 2004-12-28 | — | — | US | disclosed |
| US-20040249210-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION | 2004-12-09 | — | — | US | disclosed |
| US-6811595-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-11-02 | — | — | US | disclosed |
| US-20040158063-A1 | Alkylated tetrakis(triaminotriazine) compounds and phase change inks containing same | XEROX CORPORATION | 2004-08-12 | — | — | US | disclosed |
| US-6761758-B2 | INK COMPOSITION COMPRISING COLORANT AND PHASE CHANGE INK CARRIER; INK JET PRINTING | XEROX CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-20040075723-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20040065227-A1 | Phase change inks containing gelator additives | XEROX CORPORATION | 2004-04-08 | — | — | US | disclosed |
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040050295-A1 | ALKYLATED TETRAKIS(TRIAMINOTRIAZINE) COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | XEROX CORPORATION | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | CCNI, INO80, CCNY | TLR8 2733/4885PPARG 2828/4885PPARA 4287/4885 |
| US-20040050295-A1 | ALKYLATED TETRAKIS(TRIAMINOTRIAZINE) COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | CCNT1, CCNT2, CCNK | TLR8 3631/4885PPARG 4285/4885PPARA 4622/4885 |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | INO80, RPP30, RO60 | TLR8 3366/4885PPARG 2057/4885PPARA 3729/4885 |
| US-20040158063-A1 | Alkylated tetrakis(triaminotriazine) compounds and phase change inks containing same | CCNT1, CCNT2, CCNK | TLR8 3631/4885PPARG 4285/4885PPARA 4622/4885 |
| US-20040249210-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | NR4A1, NR0B1, RCOR1 | TLR8 1520/4885PPARG 3107/4885PPARA 3541/4885 |
| US-20040075723-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | NR4A1, NR1I3, CCNY | TLR8 1167/4885PPARG 3909/4885PPARA 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.